索拉非尼联合希罗达治疗三亚地区回、汉族中晚期原发性肝癌患者的疗效对比分析

Objective To compare the clinical efficacy of sorafenib combined with capecitabine in Hui versus Han residents with advanced hepatocellular carcinoma (HCC) in Sanya, Hainan, China- Methods A total of 96 Hui and Han residents with advanced HCC took oral capecitabine 1500 mg/m² twice daily for 14 days followed by a 7 - day withdrawal, which was repeated at least twice; besides, sorafenib was given orally at a dose of 400 mg twice daily until tumor progression occurred- Comparison of continuous data between the two groups was made by t test, while comparison of categorical data was made by chi - square test- Results In the two groups of Hui and Han patients, the rates of alpha - fetoprotein reduction were 60.9% and 40.0%, respectively (X² = 4.173, P = 0.041); the rates of serum ferritin reduction were 50.0% and 30.0%, respectively (X² = 4.007, P = 0.027); the rates of tumor regression were 54.3% and 34.0% as shown by CT (X² =4.030, P = 0.045) ; the response rates were 32.6% and 14.0%, respectively (X² =4.697, P = 0.030) - Survival analysis suggested the combination of sorafenib and capecitabine had provided a significantly higher overall survival rate in Hui patients than in Han patients ( P < 0.05 ). There was no significant difference in the incidence of adverse reactions between the two groups (P > 0.05 ). Conclusion In Sanya, a combination of sorafenib and capecitabine has better efficacy in Hui patients with advanced HCC than in Han patients, and the former have a higher overall survival rate. [ABSTRACT FROM AUTHOR]